This is further supported by a more recent study, showing that M2 TAMs augment triple negative breast cancer growth and promote angiogenesis via vascular endothelial growth factor (VEGF)/acutely transforming retrovirus (AKT)/mammalian target of rapamycin (mTOR) signalling pathway (56). This evidence concerns the gene MTOR and triple-negative breast carcinoma.